All In Biotech

NDA 022580 · Vivus LLC

Qsymia

Phentermine Hydrochloride, Topiramate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jul 17, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

73

8 Phase 3, 5 recruiting

FAERS reports

6,540

887 serious, 16 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition Limitations of Use The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. Phentermine and topiramate extended-release capsules are a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity ( 1 ). Adults with overweight in the presence of at least one weight-related comorbid condition ( 1 ). Limitations of Use: The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established ( 1 ). The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established ( 1 ).

Mechanism: Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." The effect of phentermine on weight reduction and long-term maintenance of body weight is likely mediated by release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The exact mechanism of action is not known. The precise mechanism of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 15MG BASE; TOPIRAMATE 92MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 7.5MG BASE; TOPIRAMATE 46MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 11.25MG BASE; TOPIRAMATE 69MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 3.75MG BASE; TOPIRAMATE 23MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Phentermine" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache408
  • paraesthesia349
  • dry mouth312
  • insomnia311
  • dizziness297
  • weight increased295
  • feeling abnormal263
  • inappropriate schedule of product administration257
  • fatigue232
  • constipation228
  • nausea224
  • anxiety212

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20122
2013107
2014302
2015398
2016366
2017271
2018183
2019162
2020226
2021262
2022366
2023794
20241,134
20251,186
2026781

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 135 on PubMed

Sponsor: Vivus LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.